Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Extracts possessing the capacity to hemagglutinate normal human erythrocytes were recovered from Haemophilus aegyptius by treatment with either diethylene glycol or acetone. Antisera prepared against these extracts or the unextracted bacterial cell inhibited hemagglutination by homologous and heterologous antigens. Microgel diffusions indicated the presence of identical components in each extract as expressed by lines of identity between antisera to each fraction. The hemagglutinin was identified as a lipopolysaccharide, 42% lipid and 57% carbohydrate. The determination of 6% phosphorus in the lipid fraction identified it as containing phospholipid.
 ...
PMID:Hemagglutinating property of Haemophilus aegyptius. 497 Sep 92

Mild hydrolysis of Haemophilus influenzae type a lipopolysaccharide by ion exchangers yielded a lipid A extracted by chloroform. It contained phosphorus, glucosamine, and fatty acids. Myristic, palmitic, 3-hydroxymyristic, and oleic acids and two other unidentified long-chain fatty acids were found. The free lipid A was not toxic for mice at doses of up to 50 mg/kg and did not provoke a Shwartzman reaction. The Limulus test activity was positive up to 10(-12) g/ml, but the pyrogenicity in rabbits was lower than with the original lipopolysaccharide. However, the lipid A did induced a mitogenic response and polyclonal B-cell activation in mouse spleen cell cultures. Complexing lipid A with bovine serum albumin gave a nontoxic preparation which lost these immunological activities. Immunochemical studies showed that the major reactive determinants of this lipid-protein complex were altered after such a linkage. Consequently, the nontoxic and mitogenic lipid A isolated from H. influenzae type a did not exhibit all of the classical activities of lipid A preparations.
 ...
PMID:Characteristics of a lipid preparation (lipid A) from Haemophilus influenzae type a lipopolysaccharide. 679 Apr 42

This study describes a method for the determination of phosphorus in lyophilized Haemophilus influenzae type b conjugate vaccines by inductively coupled plasma-atomic emission spectroscopy (ICP-AES). The concentration of polysaccharide is directly related to the concentration of phosphorus as measured in the laboratory. Phosphorus is present in the polyribosyl-ribitol phosphate (PRP) group of the Haemophilus influenzae type b conjugate vaccine. The repeating unit of PRP is 3-B-D ribose[1-1]ribitol-5-phosphate. Phosphorus in the final container is measured in microg per dose. The amount of PRP is calculated from this and reported in microg per dose. The Haemophilus influenzae type b conjugate vaccine was analyzed for phosphorus content within the range of 1.34 to 2.02 microg phosphorus per ml. The relative difference of phosphorus concentrations determined by the ICP-AES method from the phosphorus concentrations determined by the traditional colorimetric molybdate method ranged from 2.2 to 10.6%. Phosphorus spike recovery for the vaccine ranged from 93 to 99% (1.93+/-0.13 microg P/ml). The phosphorus determination of NIST SRM 3139 phosphorus spectrometric solution differed by 3.0% from the certified phosphorus value (10.00 mg P/ml).
 ...
PMID:The determination of phosphorus in Haemophilus influenzae type b conjugate vaccines by inductively coupled plasma-atomic emission spectrometry. 1123 58

Haemophilus influenzae b conjugate vaccines (Hib) are almost entirely evaluated by physico-chemical methods to ensure the consistency of manufacture of batches. As different assays are employed for the quantification of Hib capsular polysaccharide PRP (polyribosyl ribitol phosphate; 5-D-ribitol-(1-->1)-beta-D-ribose-3-phosphate) in final formulations and bulk components, there was deemed a need for an International Standard of Hib PRP polysaccharide to be made available. Ten laboratories from 8 different countries participated in a collaborative study to determine the PRP content and assess the suitability of a candidate International Standard PRP preparation (02/208). The results illustrate that a reduction in between-laboratory variability could be achieved by use of a common reference preparation and data analysis showed no significant differences in the values obtained by the different assays: ribose, phosphorus, and high performance anion exchange chromatography-pulsed amperometric detection (HPAEC-PAD), suggesting the suitability of the proposed reference for use across these assays for quantification of PRP content in Hib vaccines. On the basis of the results of this study, the First International Standard for PRP, NIBSC Code 02/208, has been established by the Expert Committee of Biological Standards of the World Health Organisation, with a content of 4.933+/-0.267mg/ampoule, as determined by the ribose assays carried out by 7 of the participating laboratories.
 ...
PMID:Evaluation of the saccharide content and stability of the first WHO International Standard for Haemophilus influenzae b capsular polysaccharide. 1733 5